Auris Regains Compliance with Nasdaq's Minimum Bid Price Requirement
29 mars 2018 07h00 HE | Auris Medical AG
Zug, Switzerland, March 29, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...
Auris Medical Provides Business Update and Reports Fourth Quarter and Full Year 2017 Financial Results
22 mars 2018 09h05 HE | Auris Medical AG
Initiated second Phase 1 clinical trial with intranasal betahistine Preparing for health authority discussions of regulatory pathway for AM-111 program Analyses of Keyzilen® trial outcomes...
Auris Medical Provides Business Update
13 mars 2018 16h15 HE | Auris Medical AG
Zug, Switzerland, March 13, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...
Auris Medical to Host Key Opinion Leader Call Focused on Keyzilen® Tinnitus Program on March 5, 2018
26 févr. 2018 08h30 HE | Auris Medical AG
Zug, Switzerland, February 26, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Announces Extraordinary General Meeting of Shareholders
09 févr. 2018 08h00 HE | Auris Medical AG
Proposed capital restructuring to ensure compliance with Nasdaq minimum bid price rule contingent on Company's share price development Alain Munoz proposed as new member of the Board of the...
Auris Medical Reports New Data Highlighting Superior Bioavailability of AM-125 Compared to Oral Betahistine
07 févr. 2018 09h10 HE | Auris Medical AG
Single dose animal study demonstrates 5 to 35 times higher bioavailability of intranasal betahistine relative to oral betahistine Bioavailability of intranasal betahistine in humans estimated...
Auris Medical Announces Pricing of $5.5 Million Registered Direct Offering
29 janv. 2018 16h30 HE | Auris Medical AG
  Zug, Switzerland, January 29, 2018 - Auris Medical Holding AG ("Auris Medical", NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...
Auris Medical Provides Update on AM-111 Development Program
04 janv. 2018 07h30 HE | Auris Medical AG
Further analyses from HEALOS Phase 3 clinical trial support AM-111's otoprotective effects in patients with profound acute hearing loss Clinically and statistically significant improvement in...
Auris Medical News Release - Auris Medical to Provide Update on Its AM-111 Hearing Loss Program on Thursday, January 4, 2018
28 déc. 2017 08h30 HE | Auris Medical AG
Zug, Switzerland, Dec. 28, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Reports Top-Line Results from Phase 3 Trial of AM-111 in Sudden Deafness
28 nov. 2017 06h40 HE | Auris Medical AG
HEALOS trial did not meet primary efficacy endpoint  in overall study population Clinically and statistically significant improvement in subpopulation of patients with profound acute hearing...